Rachel Humphrey, M.D.

Dr. Humphrey is a member of the Board of Directors at Sporos Bioventures. She currently serves as the Chief Executive Officer of Normunity, Inc., an immuno-oncology company, and is a member of the Board of Directors of Pyxis Therapeutics. Before Normunity, she served as Chief Medical Officer at Black Diamond Therapeutics, a precision oncology medicine company. Prior to that, Dr. Humphrey served as Chief Medical Officer and as a member of the Board of Directors of CytomX Therapeutics, Inc, and as a member of the Board of Directors of Xilio Therapeutics. Previously, she held numerous senior leadership roles in cancer drug development, including Vice President, Head of Immuno-Oncology at Eli Lilly and Company, SVP and Head of Immuno-Oncology at AstraZeneca, Executive VP and Chief Medical Officer at Mirati Therapeutics, and VP, Clinical Development at Bristol-Myers Squibb (BMS). Dr. Humphrey holds an M.D. from Case Western Reserve University and a B.A. from Harvard University. She received her training in internal medicine at The Johns Hopkins Hospital and started her career as an oncology fellow and staff physician at the National Cancer Institute in Bethesda, MD.